Targeted Induction of Right Ventricular Cardiomyocytes from hPSCs: Insights from Saito et al. (2025)

Study Background and Research Question

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are increasingly vital in cardiovascular research, particularly for disease modeling, drug screening, and regenerative therapies. However, most differentiation protocols yield heterogeneous populations or are biased toward left ventricular-like (LV-like) phenotypes. This is a significant limitation, as right ventricular (RV) pathologies—such as arrhythmogenic right ventricular cardiomyopathy and right heart failure—have unique developmental and functional features not recapitulated by LV-like cells. Saito et al. (2025) address the critical knowledge gap: can human pluripotent stem cells be efficiently directed to generate RV-like cardiomyocytes, and how do these compare functionally and molecularly to LV-like counterparts (Saito et al., 2025)?

Key Innovation from the Reference Study

The central innovation in this work is the modification of a widely used cardiac differentiation method—the GiWi protocol (GSK3β inhibition followed by Wnt inhibition)—to selectively promote the formation of second heart field (SHF)-like progenitors, which give rise to RV cardiomyocytes. By introducing insulin or bone morphogenetic protein (BMP) antagonists during the mesoderm induction phase, the authors were able to suppress first heart field (FHF) marker expression and upregulate SHF markers, steering differentiation toward a right ventricular lineage (Saito et al., 2025).

Methods and Experimental Design Insights

Saito et al. employed a modified stepwise differentiation protocol:

• Initiation with GSK3β inhibitor (to activate Wnt signaling and promote mesoderm formation).
• Subsequent inhibition of Wnt to drive cardiac fate.
• Critical alteration: Addition of insulin or BMP antagonists during mesoderm induction, specifically to modulate endogenous BMP activity.

They assessed cardiac progenitor identity using established FHF and SHF transcriptional markers (e.g., TBX5, NKX2-5), and characterized the resulting hPSC-CMs using chamber-specific genes, functional assays (spontaneous contraction rates, Ca²⁺ transients), and morphological measurements. The approach allowed direct comparison between LV-like and RV-like cardiomyocytes derived from the same pluripotent source (Saito et al., 2025).

Protocol Parameters

• differentiation protocol | GiWi with BMP inhibition | hPSC-CM induction | Enhances RV-like (SHF) fate | paper
• insulin/BMP antagonist addition | during mesoderm induction (timing as per protocol) | SHF progenitor enrichment | Downregulates FHF markers, upregulates SHF markers | paper
• cardiac marker assessment | TBX5, NKX2-5, others | lineage verification | Distinguishes FHF vs. SHF origin | paper
• functional readouts | contraction rate, Ca²⁺ flux, cell size | phenotype validation | Confirms RV-like functional identity | paper
• optimized sodium channel modulator use | 20–40 μM veratridine, 24 h | excitability assays in hPSC-CMs | Recommended by workflow; enables sodium channel dynamics assessment | workflow_recommendation

Core Findings and Why They Matter

The modified protocol successfully redirected differentiation toward SHF-like cardiac progenitors, resulting in hPSC-CMs with a molecular, functional, and morphological signature reminiscent of native RV cardiomyocytes. Specifically:

• Progenitor cells exhibited decreased FHF marker expression and increased SHF marker expression.
• Derived CMs expressed RV-specific genes, displayed higher spontaneous contraction rates, distinct Ca²⁺ transients, and smaller cell size compared to control (LV-like) CMs.
• This is the first demonstration of a reproducible, chemically defined strategy to selectively generate RV-like hPSC-CMs (Saito et al., 2025).

These results have immediate implications for modeling RV-specific diseases, understanding chamber-specific cardiac development, and enabling precise pharmacological screening.

Comparison with Existing Internal Articles

Several internal resources discuss the utility of sodium channel modulators—such as veratridine—for probing cardiomyocyte excitability and chamber-specific function.

• For example, “Veratridine: Unlocking Chamber-Specific Sodium Channel Dynamics” highlights the value of precision sodium channel openers in distinguishing functional phenotypes between LV and RV cardiomyocytes. Saito et al.'s protocol directly enables such nuanced studies by providing RV-like hPSC-CMs as a robust platform for sodium channel dynamics research.
• “Veratridine: Voltage-Gated Sodium Channel Opener in Research” further addresses the need for high-fidelity sodium channel assays using well-characterized cell models—a requirement now more feasible with chamber-specific hPSC-CMs generated via Saito et al.'s approach.

Unlike these internal guides, which primarily focus on sodium channel pharmacology and protocol troubleshooting, the reference study delivers foundational evidence for reliably generating the required cell types to support such advanced applications.

Limitations and Transferability

While the study provides a robust protocol for RV-like cardiomyocyte induction, several considerations remain:

• Long-term maturation state: The extent to which hPSC-derived RV-like CMs recapitulate adult RV physiology, especially regarding electrophysiological maturity and response to stress, requires further investigation (Saito et al., 2025).
• Line-to-line and batch variability: As with all pluripotent stem cell protocols, differentiation efficiency and phenotypic fidelity may vary with cell line, warranting protocol optimization.
• Transferability to disease modeling: While the platform is promising for RV disease studies, disease-specific phenotypes must be validated in patient-derived hPSC lines.
• Functional integration: The study focuses on in vitro phenotypes; further work is needed to assess integration and function in tissue or organoid models.

Research Support Resources

For researchers aiming to study sodium channel dynamics or pharmacological responses in chamber-specific hPSC-CMs, validated reagents are critical. Veratridine (SKU B7219) from APExBIO is a well-characterized voltage-gated sodium channel opener suitable for use in hPSC-CM excitability and excitotoxicity assays (source: product_spec). When applying the Saito et al. protocol, veratridine can be employed at 20–40 μM for 24 h to probe sodium channel responses in RV- or LV-like cardiomyocytes, supporting workflow reproducibility (source: workflow_recommendation). Always refer to primary literature and validated product specifications for detailed experimental design.